Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy — Stella

Home/BRCA1 Mutation/

View on ClinicalTrials.gov

Recruiting

Back to BRCA1 Mutation trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(2 sites)

United States

UNC Chapel Hill Health System, Chapel Hill, North Carolina

Duke University Health System, Durham, North Carolina

Key details

Sponsor

Duke University

Enrollment target

~50 participants

Started

September 2025

Primary completion

July 2026

Age range

19 Years – 50 Years

Sex

Female only

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.